Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences?

J.M. Bakker, R. Lieverse, C. Menne-Lothmann, W. Viechtbauer, E. Pishva, G. Kenis, N. Geschwind, F. Peeters, J. van Os, M. Wichers

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)

Abstract

Positive affect (PA) has an important role in resilience against depression and has been shown to increase with mindfulness-based cognitive therapy (MBCT). To elucidate the underlying mechanisms of change in PA as well as develop insights that may benefit personalized medicine, the current study examined the contribution of genetic variation to individual differences in change in PA in response to MBCT. Individuals (n=126) with residual depressive symptoms were randomized to either an MBCT group or treatment as usual. PA was assessed using experience sampling methodology (ESM). Single-nucleotide polymorphisms (SNPs) in genes known to be involved in reward functioning were selected. SNPs in the genes for brain-derived neurotrophic factor (BDNF), the muscarinic acetylcholine receptor M2 (CHRM2), the dopamine receptor D4 (DRD4) and the mu1 opioid receptor (OPRM1) significantly moderated the impact of treatment condition over time on PA. Genetic variation in the genes for CHRM2 and OPRM1 specifically had an impact on the level of PA following MBCT. The current study shows that variation in response to MBCT may be contingent on genetic factors associated with the regulation of PA. These findings contribute to our understanding of the processes moderating response to treatment and prediction of treatment outcome.
Original languageEnglish
Article numbere384
Number of pages10
JournalTranslational Psychiatry
Volume4
DOIs
Publication statusPublished - Apr 2014

Keywords

  • RANDOMIZED CONTROLLED-TRIAL
  • MESOLIMBIC DOPAMINE SYSTEM
  • MAJOR DEPRESSIVE DISORDER
  • M2 CHRM2 GENE
  • ALCOHOL DEPENDENCE
  • RECEPTOR GENE
  • AUTORADIOGRAPHIC LOCALIZATION
  • MOMENTARY ASSESSMENT
  • INCENTIVE SALIENCE
  • REWARD EXPERIENCE

Cite this

@article{f9790047feb74de6a9ce59c0ce623a40,
title = "Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences?",
abstract = "Positive affect (PA) has an important role in resilience against depression and has been shown to increase with mindfulness-based cognitive therapy (MBCT). To elucidate the underlying mechanisms of change in PA as well as develop insights that may benefit personalized medicine, the current study examined the contribution of genetic variation to individual differences in change in PA in response to MBCT. Individuals (n=126) with residual depressive symptoms were randomized to either an MBCT group or treatment as usual. PA was assessed using experience sampling methodology (ESM). Single-nucleotide polymorphisms (SNPs) in genes known to be involved in reward functioning were selected. SNPs in the genes for brain-derived neurotrophic factor (BDNF), the muscarinic acetylcholine receptor M2 (CHRM2), the dopamine receptor D4 (DRD4) and the mu1 opioid receptor (OPRM1) significantly moderated the impact of treatment condition over time on PA. Genetic variation in the genes for CHRM2 and OPRM1 specifically had an impact on the level of PA following MBCT. The current study shows that variation in response to MBCT may be contingent on genetic factors associated with the regulation of PA. These findings contribute to our understanding of the processes moderating response to treatment and prediction of treatment outcome.",
keywords = "RANDOMIZED CONTROLLED-TRIAL, MESOLIMBIC DOPAMINE SYSTEM, MAJOR DEPRESSIVE DISORDER, M2 CHRM2 GENE, ALCOHOL DEPENDENCE, RECEPTOR GENE, AUTORADIOGRAPHIC LOCALIZATION, MOMENTARY ASSESSMENT, INCENTIVE SALIENCE, REWARD EXPERIENCE",
author = "J.M. Bakker and R. Lieverse and C. Menne-Lothmann and W. Viechtbauer and E. Pishva and G. Kenis and N. Geschwind and F. Peeters and {van Os}, J. and M. Wichers",
year = "2014",
month = "4",
doi = "10.1038/tp.2014.23",
language = "English",
volume = "4",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",

}

Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences? / Bakker, J.M.; Lieverse, R.; Menne-Lothmann, C.; Viechtbauer, W.; Pishva, E.; Kenis, G.; Geschwind, N.; Peeters, F.; van Os, J.; Wichers, M.

In: Translational Psychiatry, Vol. 4, e384, 04.2014.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Therapygenetics in mindfulness-based cognitive therapy: do genes have an impact on therapy-induced change in real-life positive affective experiences?

AU - Bakker, J.M.

AU - Lieverse, R.

AU - Menne-Lothmann, C.

AU - Viechtbauer, W.

AU - Pishva, E.

AU - Kenis, G.

AU - Geschwind, N.

AU - Peeters, F.

AU - van Os, J.

AU - Wichers, M.

PY - 2014/4

Y1 - 2014/4

N2 - Positive affect (PA) has an important role in resilience against depression and has been shown to increase with mindfulness-based cognitive therapy (MBCT). To elucidate the underlying mechanisms of change in PA as well as develop insights that may benefit personalized medicine, the current study examined the contribution of genetic variation to individual differences in change in PA in response to MBCT. Individuals (n=126) with residual depressive symptoms were randomized to either an MBCT group or treatment as usual. PA was assessed using experience sampling methodology (ESM). Single-nucleotide polymorphisms (SNPs) in genes known to be involved in reward functioning were selected. SNPs in the genes for brain-derived neurotrophic factor (BDNF), the muscarinic acetylcholine receptor M2 (CHRM2), the dopamine receptor D4 (DRD4) and the mu1 opioid receptor (OPRM1) significantly moderated the impact of treatment condition over time on PA. Genetic variation in the genes for CHRM2 and OPRM1 specifically had an impact on the level of PA following MBCT. The current study shows that variation in response to MBCT may be contingent on genetic factors associated with the regulation of PA. These findings contribute to our understanding of the processes moderating response to treatment and prediction of treatment outcome.

AB - Positive affect (PA) has an important role in resilience against depression and has been shown to increase with mindfulness-based cognitive therapy (MBCT). To elucidate the underlying mechanisms of change in PA as well as develop insights that may benefit personalized medicine, the current study examined the contribution of genetic variation to individual differences in change in PA in response to MBCT. Individuals (n=126) with residual depressive symptoms were randomized to either an MBCT group or treatment as usual. PA was assessed using experience sampling methodology (ESM). Single-nucleotide polymorphisms (SNPs) in genes known to be involved in reward functioning were selected. SNPs in the genes for brain-derived neurotrophic factor (BDNF), the muscarinic acetylcholine receptor M2 (CHRM2), the dopamine receptor D4 (DRD4) and the mu1 opioid receptor (OPRM1) significantly moderated the impact of treatment condition over time on PA. Genetic variation in the genes for CHRM2 and OPRM1 specifically had an impact on the level of PA following MBCT. The current study shows that variation in response to MBCT may be contingent on genetic factors associated with the regulation of PA. These findings contribute to our understanding of the processes moderating response to treatment and prediction of treatment outcome.

KW - RANDOMIZED CONTROLLED-TRIAL

KW - MESOLIMBIC DOPAMINE SYSTEM

KW - MAJOR DEPRESSIVE DISORDER

KW - M2 CHRM2 GENE

KW - ALCOHOL DEPENDENCE

KW - RECEPTOR GENE

KW - AUTORADIOGRAPHIC LOCALIZATION

KW - MOMENTARY ASSESSMENT

KW - INCENTIVE SALIENCE

KW - REWARD EXPERIENCE

U2 - 10.1038/tp.2014.23

DO - 10.1038/tp.2014.23

M3 - Article

VL - 4

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

M1 - e384

ER -